Voloridge Investment Management LLC Has $28.90 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Voloridge Investment Management LLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 107.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 156,574 shares of the medical research company's stock after acquiring an additional 80,918 shares during the quarter. Voloridge Investment Management LLC owned approximately 0.31% of Charles River Laboratories International worth $28,904,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Optiver Holding B.V. bought a new stake in shares of Charles River Laboratories International during the 4th quarter worth about $37,000. GeoWealth Management LLC lifted its holdings in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new stake in Charles River Laboratories International in the 4th quarter worth approximately $48,000. Tortoise Investment Management LLC boosted its position in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after purchasing an additional 115 shares during the period. Finally, Huntington National Bank grew its holdings in Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after purchasing an additional 164 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL traded up $2.62 during trading hours on Tuesday, reaching $139.35. The stock had a trading volume of 131,811 shares, compared to its average volume of 990,560. The company has a market cap of $6.84 billion, a price-to-earnings ratio of 930.03, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The business's fifty day moving average is $131.30 and its two-hundred day moving average is $162.22. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same quarter in the previous year, the firm posted $2.27 EPS. The business's revenue for the quarter was down 2.7% on a year-over-year basis. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CRL. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a research note on Wednesday, May 14th. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Mizuho dropped their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. Finally, JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and a consensus price target of $171.85.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).